SCHEDULE: L1 Capital Fund Discloses 4.99% Stake in Aptevo
Beneficial Ownership Report (Amendment)
L1 Capital Global Opportunities Master Fund, Ltd. reported a 4.99% beneficial ownership stake in Aptevo Therapeutics Inc. common stock through warrants.
Summary
- L1 Capital Global Opportunities Master Fund, Ltd. reported beneficial ownership of 164,300 shares of Aptevo Therapeutics Inc. common stock.
- This represents 4.99% of Aptevo's outstanding common stock, based on 3,287,918 shares outstanding as of August 11, 2025.
- The reported shares are warrants, subject to a 4.99% beneficial ownership limitation.
- An additional 1,345,075 warrants are held but not included in the reported beneficial ownership due to the same 4.99% limitation.
- This filing is an Amendment No. 1 to a previous Schedule 13G filed on June 23, 2025, which covered 285,000 shares underlying warrants purchased on June 18, 2025.
- The securities were not acquired for the purpose of changing or influencing control of Aptevo Therapeutics Inc.
Sentiment
Score: 5
Explanation: This is a neutral, factual disclosure of beneficial ownership, indicating a significant but non-controlling stake.
Future Outlook
NA
Industry Context
This is a standard disclosure of a significant ownership stake by an investment fund in a biotechnology company, common for institutional investors managing portfolios and adhering to regulatory reporting thresholds.
Stakeholder Impact
- Shareholders: Provides transparency regarding a significant institutional investor's stake, which could be seen as a vote of confidence or a potential source of future liquidity/pressure depending on the investor's strategy.
Key Dates
| Date | Description |
|---|---|
| June 18, 2025 | Date warrants were purchased, related to the original Schedule 13G filing. |
| June 23, 2025 | Date the original Schedule 13G was filed with the SEC. |
| August 11, 2025 | Date of Aptevo Therapeutics Inc.'s Quarterly Report on Form 10-Q, used for outstanding common stock count. |
| August 14, 2025 | Date of event requiring the filing of this Schedule 13G Amendment No. 1. |
Keywords
Aptevo Therapeutics, L1 Capital, Schedule 13G, Beneficial Ownership, Common Stock, Warrants, SEC Filing, Biotechnology, Pharmaceutical
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.